We describe the efficacy and safety of ramucirumab with eribulin versus eribulin monotherapy as third-to fifthline therapy in women with advanced breast cancer. The primary end point of progression-free survival was not met. Screening for brain metastases upon trial entry showed an unanticipated prevalence of asymptomatic brain disease, raising new considerations for screening in late-stage metastatic breast cancer irrespective of HER2 or hormone receptor status. Background: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third-to fifth-line therapy in women with advanced breast cancer. Patients and Methods: In this randomized (1:1), open-label, phase II study, US women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1.4 mg/m 2 intravenously on days 1 and 8; ramucirumab 10 mg/kg intravenously on day 1). Randomization was stratified according to previous antiangiogenic therapy and triple-negative status. The primary end point was progression-free survival (PFS) in the intention to treat population. Results: One hundred forty-one women were randomized to ramucirumab with eribulin (n ¼ 71) or eribulin alone (n ¼ 70 Clinical Breast Cancer December 2016 -471 with 11.5 months (95% CI, 9.0-17.3) in patients who received eribulin alone (HR, 0.91; 95% CI, 0.59-1.41; P ¼ .68); objective response rate was 21% (13 of 62 patients) for the combination and 28% (17 of 60 patients) for eribulin alone. No unexpected toxicity was identified for the combination. Conclusion: Ramucirumab combined with eribulin did not significantly improve PFS in advanced MBC.
Introduction
In 2016, in the United States, more than 240,000 women will be diagnosed with breast cancer and approximately 40,000 deaths will occur from metastatic breast cancer, with a 25% 5-year survival estimated for women of all races. 1 The pursuit of beneficial therapeutic regimens for metastatic breast cancer has been a compelling campaign in the oncology community. In human breast cancer, intensive neovascularizations and tumor angiogenesis correlate with metastases and poor prognosis. 2, 3 Strong preclinical and clinical evidence suggests vascular endothelial growth factor (VEGF) and angiogenesis play key roles in breast cancer growth, invasion, and metastasis; this evidence paired with strategies of VEGF inhibition showed improved outcomes in early preclinical models. 4, 5 However, antiangiogenesis strategy success in other tumor types, including lung, cervical, colorectal, glioblastoma, and renal cancers, [6] [7] [8] [9] [10] has yet to be clearly replicated in metastatic breast cancer. After more than a decade of unsuccessful attempts to show an overall survival advantage, [11] [12] [13] [14] [15] there is currently no approved US indication for bevacizumab in breast cancer, despite evidence of improved disease control, measured according to response and progression-free survival, when combined with single-agent chemotherapy. Ramucirumab is a US Food and Drug Administration (FDA)-approved, recombinant human monoclonal antibody that binds the extracellular domain of VEGF receptor (VEGFR)-2, where it blocks receptor interaction with activating ligands (VEGF-a, VEGF-C, and VEGF-D), preventing downstream signaling involved in the formation and maintenance of aberrant blood vessels that supply tumors and maintain endothelial cell proliferation. 16 Its selectivity for VEGFR-2 sets it apart from the ligand-binding function of bevacizumab. Global phase III trials in breast, gastric, lung, hepatocellular, and colorectal cancers were undertaken, leading to ramucirumab's first FDA approval in 2014 as a single-agent treatment, or in combination with paclitaxel, for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression during or after fluoropyrimidine-or platinum-containing chemotherapy. 17, 18 Despite the efficacy of ramucirumab in gastric cancer, the recently reported Ramucirumab Overall Survival Evaluation/Translational Research In Oncology-12 (ROSE/TRIO-12) study, a randomized, placebo-controlled, phase III trial of first-line docetaxel with ramucirumab versus docetaxel in metastatic breast cancer, did not meet its primary end point of progression-free survival. 19 Eribulin is a nontaxane microtubule polymerization inhibitor with clinical efficacy and an acceptable toxicity profile that is FDAapproved as a single agent in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. 20, 21 Considering the observed efficacy of eribulin in late-stage breast cancer as well as in taxane-and anthracycline-pretreated metastatic breast cancer coupled with the potential contribution of VEGFRe2-mediated pathways in breast cancer pathogenesis, [12] [13] [14] [15] the combination of ramucirumab with eribulin was hypothesized to improve clinical outcomes in advanced metastatic breast cancer. Because of the published efficacy of bevacizumab in metastatic breast cancer studies, 22, 23 including use in combination with paclitaxel, the ramucirumab with eribulin combination was hypothesized to be active in metastatic breast cancer. The primary objective of this randomized, open-label, phase II study was to identify whether the combination of ramucirumab with eribulin would increase progression-free survival compared with eribulin alone, as third-to fifth-line therapy in patients with advanced breast cancer.
Patients and Methods

Study Design and Participants
This was a multicenter, randomized, open-label, phase II trial conducted at 44 centers in the United States. Female patients aged 18 years or older with stage III locally recurrent not amenable to curative therapy or stage IV metastatic breast cancer and 2 to 4 previous chemotherapy regimens in the advanced setting were eligible for enrollment. Previous anthracycline and taxane treatment, previous HER2-directed treatment in HER2-positive disease (unless contraindicated), normal left ventricular ejection fraction, and Eastern Cooperative Oncology Group performance status of 0 or 1 were required. Patients were eligible for inclusion if they had measurable and/or nonmeasurable disease defined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). Key exclusion criteria included uncontrolled hypertension, bevacizumab administration within 6 weeks, or a Grade ! 3 bleeding or venous thromboembolic event within 3 months before randomization. Patients with untreated and unstable central nervous system metastases within 3 months were also excluded; baseline brain imaging was required for all patients and treated brain lesions had to show no progression for ! 3 months.
The US study was approved by ethics review boards for each center, and study conduct was guided by the Guideline for Good Clinical Practice and the Declaration of Helsinki. Patients provided written informed consent before initiation of treatments.
Randomization and Masking
Patients were randomized (1:1) via a call-in interactive voice response system. Randomization was stratified according to
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Ramucirumab With Eribulin Versus Eribulin in Breast Cancer previous antiangiogenic therapy and triple-negative status (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative). This was an open-label study; therefore, patients, medical staff, investigators, and funders were unmasked to the treatment assignment.
Study Treatment and Assessments
Female patients received ramucirumab 10 mg/kg intravenously on day 1 with eribulin 1.4 mg/m 2 intravenously on days 1 and 8, or eribulin alone (1.4 mg/m 2 on days 1 and 8). The cycle was repeated every 3 weeks (21 days) until disease progression, development of disease progression, development of unacceptable toxicity, withdrawal of consent, or other withdrawal criteria were met. Dose modifications were permitted, but not required, for ramucirumab in the setting of nonelife-threatening, reversible Grade 3-4 adverse events that resolved to Grade 1 within 1 cycle. A second dose reduction to 6 mg/kg every 3 weeks was permitted for Grade 3-4 events. Ramucirumab was to be discontinued for Grade 3-4 events of hemorrhage, thromboembolism, or infusion-related reaction, and Grade 4 hypertension. Eribulin dose modifications were made according to the manufacturer's package insert. 21 Ramucirumab and/ or eribulin was allowed to continue if toxicity was considered by the investigator to not be related to that drug in the combination group.
The changes in tumor size in post-treatment tumor assessments were analyzed every 6 weeks. Imaging studies were undertaken every 6 weeks after the first dose until documented disease progression.
Safety was analyzed for all patients who received at least 1 dose of study treatment. A Safety Assessment Committee monitored the study, including review of the safety cohort data for the first 6 and then 12 patients who received 2 cycles of combination therapy. The safety and tolerability of ramucirumab and eribulin were determined by reported adverse events, physical examinations, and laboratory tests. Safety data were graded using the National Cancer InstituteCommon Terminology Criteria for Adverse Events version 4.0. Causality relationship to study drug was separately summarized.
Outcomes
The primary outcome was to compare the antitumor activity between ramucirumab and eribulin or eribulin alone, measured according to progression-free survival and defined as the time from the date of randomization until the date of objective progression defined according to RECIST, or death from any cause, whichever occurred first. Secondary efficacy outcomes included overall survival, defined as time from randomization to date of death from any cause; objective response rate, defined as the proportion of patients achieving a best overall response of partial or complete response, determined for patients with measurable disease according to RECIST; duration of response, measured from the time measurement criteria were first met for complete response/partial response (whichever was first recorded) until the first date at which the criteria for progressive disease were met (taking as a reference for progressive disease the smallest measurement recorded since the treatment started), or until death; and change in tumor size in patients with measurable disease at 6-week assessments; as well as to assess the safety and tolerability of ramucirumab with eribulin.
Statistical Analyses
The intention to treat population consisted of all eligible randomized patients, regardless of study drug administration. Assuming an increase in median progression-free survival from 3.7 months in the control group 20 to 5.6 months in the experimental group, with 1:1 randomization, 110 progression-free survival events (objective progression or deaths) conferred 80% power to detect a hazard ratio (HR) experimental/control of 0.667 with a 2-sided significance level of 0.2. For the primary analysis, we compared progression-free survival between the 2 treatment groups using a stratified log rank test at a 2-sided significance level of 0.2, with triple-negative breast cancer status and previous antiangiogenic therapy as stratification factors. Progression-free and overall survival were estimated using the KaplaneMeier method. For overall survival and duration of response, we used the same model as for the primary analysis. The objective response rate in patients with measurable disease in the experimental group was measured and compared with the control group using the CochraneManteleHaenszel test, adjusted for stratification variables. A 2-sided 95% confidence interval (CI) for the objective response rate of each arm was calculated using Fisher exact test. The percentage of patients in each group with duration of response > 12 weeks was presented with a 2-sided 95% CI.
Changes in tumor size were analyzed by calculating the log ratio of tumor size at time of assessment to tumor size at baseline for each patient. This measure was compared between treatment groups by using an analysis of covariance using previous antiangiogenic therapy and triple-negative status as factors.
We used SAS version 8.2 or later (SAS Institute, Inc, Cary, NC). This study was registered with ClinicalTrials.gov; NCT01427933.
Results
Patients
Patient enrollment began on November 11, 2011; the primary data cutoff for efficacy (progression-free survival, response) and safety was September 11, 2013 , and the final data cutoff for overall survival was July 31, 2014. Seventy-one patients in the ramucirumab with eribulin group and 70 patients in the eribulin group were in the intention to treat population ( Figure 1 ). Patients' baseline characteristics were well balanced between the 2 groups (Table 1) . There was an unanticipated rate of asymptomatic brain metastases discovered with required brain imaging at screening (20%; 47 patients with brain metastasis of 234 screened), resulting in a screen failure rate of 15% (34 of 234) for this criterion ( Figure 1 ; Table 2 ). In total, for the 47 patients with asymptomatic brain lesions, 27 of 47 (57%) were in the estrogen receptor-and/or progesterone receptor-positive group and 20 of 47 (43%) were in the triple-negative breast cancer group, with only 2 patients also in the HER2-positive group. Receptor status for the 13 randomized patients was also summarized.
Efficacy
Median progression-free survival was 4.4 months (95% CI, 3.1-6.7) in the ramucirumab with eribulin group versus 4.1 months (95% CI, 3.2-5.6) in the eribulin group, resulting in a nonsignificant HR of 0.83 (95% CI, 0.56-1.23; P ¼ .35; Table 3 ). The HRs were consistent across 4 subgroups analyzed (triple-negative status,
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Clinical Breast Cancer December 2016 -473 previous antiangiogenic therapy, visceral vs. nonvisceral sites of metastasis, and number of metastatic sites), including the prespecified stratification factors of triple-negative breast cancer status and previous antiangiogenic therapy status (Figure 2 ), noting that the study was not powered for subgroup survival analysis. The reported subgroup results numerically favored the ramucirumab combination, with the triple-negative subgroup showing a large benefit. The median overall survival for the ramucirumab with eribulin group was 13.5 months (95% CI, 10.4-17.9) versus 11.5 months (95% CI, 9.0-17.3) in the eribulin group; the HR was 0.91 (95% CI, 0.59-1.41; P ¼ .68; Table 3) .
Thirteen of 62 patients with measurable disease in the ramucirumab with eribulin group versus 17 of 60 patients in the eribulin group had a partial response, resulting in an objective response rate of 21% (95% CI, 11.7-33.2) versus 28% (95% CI, 17.5-41.4; P ¼ .39; Table 4 ). The median duration of response in the intention to treat population was 5.5 months (95% CI, 3.1-7.1) in the ramucirumab with eribulin group and 3.0 months (95% CI, 1.4-4.4) in the eribulin group; the 6-month rate for patients with response was 39.0% versus 7.1%, with a treatment effect difference of 31.8% (95% CI, 2.1-61. 6 ). An overall reduction in tumor size in both treatment arms was seen after the 6-week tumor assessment (ramucirumab with eribulin: 61% [43 of 71]; eribulin 56% [39 of 70]). The reduction in tumor size up to 36 weeks was similar.
Safety
All-cause treatment-emergent adverse events in ! 20% of patients and Grade ! 3 (in ! 5% of patients) events are listed in Table 5 . Overall, there were more events reported in the ramucirumab with eribulin group than in the eribulin group. Treatmentemergent adverse events (any grade) reported more frequently (P < .05) in the ramucirumab with eribulin group (n ¼ 69) than in the eribulin group (n ¼ 65) were headache (27 [39%] Data on treatment-emergent adverse events of special interest were collected, for safety monitoring purposes, on the basis of previously reported adverse events associated with antiangiogenic agents and other therapeutic monoclonal antibodies. Events of special interest of any grade were reported more frequently in the ramucirumab with eribulin group than in the eribulin group (see Supplemental Table 1 in the online version). Hypertension and bleeding were the most frequently reported (P < .05) events of special interest in patients who received ramucirumab (9 Treatment-emergent adverse events resulting in at least 1 dose delay or modification occurred in 38 of 69 patients (55%) treated with ramucirumab with eribulin and in 30 of 65 patients (46%) treated with eribulin. Across both treatment groups, the most frequently reported events leading to delay/modification of any study drug were fatigue, neutropenia, and neuropathy. Ramucirumab-related adverse events in 8 of 69 patients (12%) and eribulin-related adverse events in 7 of 69 patients (10%) caused dose discontinuations in the ramucirumab with eribulin group; 6 of 65 patients (9%) had dose discontinuations because of adverse events in the eribulin monotherapy group.
Discussion
In this randomized, phase II study, ramucirumab 10 mg/kg every 3 weeks combined with eribulin did not significantly improve progression-free survival, overall survival, or objective response rate as a third-to fifth-line therapy in patients with metastatic breast cancer. Not surprisingly, higher rates of fatigue, headache, hypertension, diarrhea, pyrexia, and bleeding were observed in the ramucirumab with eribulin group; however, no unexpected toxicities were observed and the safety data were consistent with those reported for ramucirumab in other trials. 17, 18, [24] [25] [26] When this trial was designed, it was believed that ramucirumab would particularly benefit breast cancer patients, especially if biomarkers could be identified that would delineate those most likely to benefit from antiangiogenic therapies. Antiangiogenic agents in the treatment of metastatic breast cancer remain controversial, with conflicting results regarding their overall effect on survival and the inability to predict which patient subpopulation might derive meaningful benefit. Similar to the results seen with the lower dose in the docetaxel/bevacizumab-based AVADO (Avastin And Docetaxel) trial, 12 a statistically nonsignificant numerical improvement in progression-free survival was seen in the ramucirumab/docetaxel group, whereas a significant improvement in objective response rate, disease control rate, and time to progression was seen in the ROSE trial. 19 A companion analysis of potential predictive biomarkers in the ROSE study and the present metastatic breast cancer phase II study is pending that might potentially identify a patient subpopulation for whom a ramucirumab treatment strategy in breast cancer is beneficial. Early in the conduct of the study, 13 patients were randomized having either treated and stable brain lesions, or protocol violations. Many were discovered randomized for whom baseline brain imaging was not completed. When these errors were found, usually within the first cycle, the patients immediately underwent "delayed" brain imaging and, at times, a brain lesion was found. The study reported on the intention to treat population and patients with protocol violations were still included in the analysis. Despite the lack of significant improvements in progression-free survival with the combination of ramucirumab in the recent metastatic breast cancer studies, other solid tumor trials highlight the efficacy and safety of ramucirumab. 17, 18, [24] [25] [26] The phase III REVEL (ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy) trial, using the same dose and schedule of ramucirumab combined with docetaxel as in the ROSE trial, significantly prolonged survival in patients with stage IV nonesmall-cell lung cancer, compared with those treated with docetaxel alone, and led to FDA approval in the United States. 25 In addition, the placebo-controlled, phase III REGARD (ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) and RAINBOW 
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(ramucirumab as a single agent, or in combination with paclitaxel, in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy) studies led to the FDA approval of ramucirumab either as a single agent at 8 mg/kg every 2 weeks or in combination with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose disease had progressed despite fluoropyrimidine-or platinum-containing chemotherapy. 17, 18 Also, a significant overall survival and progression-free survival advantage was noted with the combination of ramucirumab with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in the RAISE (ramucirumab in combination with FOLFIRI in patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine) trial, which evaluated ramucirumab as second-line therapy for patients with metastatic colorectal carcinoma in whom first-line oxaliplatin-based chemotherapy with bevacizumab had failed. 26 In all patient populations, including those in the current study, ramucirumab resulted in predictable and manageable toxicities. 17, 18, [24] [25] [26] Cancer biology remains complex, with different tumor types showing varied responses. Ultimately, it is critical to understand the tumor biology and, perhaps, individual patient characteristics that will allow determination and prediction of clinical benefit with a VEGF strategy, which currently remains elusive. This randomized, phase II trial had several inherent limitations. The study population in this trial was a heterogenous group, with heavily pretreated patients. Therapy tested in patients who receive later lines of therapy might be less effective because of the activation of a variety of resistance mechanisms, which are poorly understood and might contribute to cancer progression. Although there are numerous mechanisms of resistance, preclinical models of eribulin activity have shown that CD31, which facilitates vascularization of capillary beds, and carbonic anhydrase 9 (CA9), a hypoxia marker, both play roles in capillary proliferation in hypoxic, poorly vascularized areas, particularly tumor cores. 27 However, although a decrease in CA9 was seen in preclinical studies with eribulin exposure, an advantage for eribulin with ramucirumab was not evident in this study. Thus a clearer understanding of the biology of this combination might provide further insight into this observed lack of benefit. Drugs that seemingly demonstrate no overall benefit might benefit subgroups of patients, but identifying these subsets remains challenging. In this trial, all subgroup results were numerically in favor of the ramucirumab combination (Figure 2) . Thus, the ability to select patients who might benefit from antiangiogenic therapy might be the key. Identification of reliable biomarkers to assist in the selection and evaluation of the activity of these agents remains elusive, but might lead to the determination of reliable end points.
In this trial, ramucirumab treatment was assessed in an unselected patient population, which might have obscured its potential benefit in a subset population. Despite an extensive search for biomarkers, no convincing candidates have been identified. In lung and colon cancers, bevacizumab is more effective with select chemotherapy pairing. 7, 28, 29 Similarly, eribulin might not be the optimal chemotherapeutic partner for ramucirumab. Interestingly, our study had an unanticipated number of women with asymptomatic brain metastases at screening, irrespective of the underlying HER2 or hormone receptor status. Current National Comprehensive Cancer Network guidelines specify brain magnetic resonance imaging for suspicious central nervous system symptoms 30 The prevalence of incidental asymptomatic brain disease in this study might prompt considerations for future studies in metastatic breast cancer on the role of screening and therapy for asymptomatic brain metastases in late-stage metastatic breast cancer, regardless of tumor receptor status.
Conclusion
Metastatic breast cancer clinical trial results to date do not support the combination of ramucirumab at 10 mg/kg every 3 weeks with chemotherapy. Questions remain as to whether the VEGF pathway is a valid target in metastatic breast cancer and whether a single-targeted agent is optimal to effectively inhibit VEGFmediated signaling. Furthermore, the VEGF pathway likely is not unilaterally essential for cell proliferation, because of the existence of parallel and escape pathways in tumors. Thus, it is imperative to evaluate quantitative biomarkers of response to anti-VEGF strategies, as well as to develop an understanding of the molecular mechanisms of activity and resistance. Perhaps insight might be gained into an understanding of the chemosensitization effects at the cellular and molecular levels and the likelihood that combinations of targeted agents will or will not be necessary to optimize therapeutic efficacy and to sufficiently affect these mechanisms. Serial tumor biopsies to more comprehensively understand the natural history spectrum of tumor biology at baseline and throughout treatment are critical to advancing therapies for metastatic breast cancer. Only then might we expand and improve our understanding of VEGF pathway inhibitors and refine the use of this targeted therapy in breast tumors.
Clinical Practice Points
Evidence suggests that angiogenesis plays a key role in breast cancer, and intensive neovascularizations and tumor angiogenesis correlate with metastases and poor prognosis. Ramucirumab is a human monoclonal antibody that inhibits ligand activation of the VEGFR-2, and is currently approved by the FDA for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma, metastatic colorectal cancer, and metastatic nonesmall-cell lung cancer. Eribulin is approved by the FDA as a single agent in patients with metastatic breast cancer who were previously treated with an anthracycline and a taxane. The published efficacy of bevacizumab in combination with paclitaxel in metastatic breast cancer formed the rationale to explore the ramucirumab with eribulin combination as third-to fifth-line therapy in women with advanced breast cancer. In our multicenter, randomized, open-label, phase II trial of ramucirumab with eribulin versus eribulin alone, the combination showed acceptable toxicity but failed to meet the primary end point of improved progression-free survival. Our study had an unanticipated number of women with asymptomatic brain metastases at screening, irrespective of the underlying hormone or HER2 receptor status. Further research into the role of quantitative biomarkers of response to anti-VEGF strategies, as well as developing an understanding of the molecular mechanisms of activity and resistance are required.
